Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Madrigal Pharmaceuticals (MDGL) Return on Equity (2019 - 2025)

Madrigal Pharmaceuticals (MDGL) has disclosed Return on Equity for 12 consecutive years, with 0.46% as the latest value for Q4 2025.

  • On a quarterly basis, Return on Equity rose 14.0% to 0.46% in Q4 2025 year-over-year; TTM through Dec 2025 was 0.46%, a 14.0% increase, with the full-year FY2025 number at 0.42%, up 38.0% from a year prior.
  • Return on Equity was 0.46% for Q4 2025 at Madrigal Pharmaceuticals, down from 0.43% in the prior quarter.
  • In the past five years, Return on Equity ranged from a high of 0.4% in Q2 2025 to a low of 5.82% in Q3 2022.
  • A 5-year average of 1.61% and a median of 0.91% in 2021 define the central range for Return on Equity.
  • Peak YoY movement for Return on Equity: plummeted -488bps in 2022, then surged 489bps in 2024.
  • Madrigal Pharmaceuticals' Return on Equity stood at 1.12% in 2021, then crashed by -153bps to 2.84% in 2022, then skyrocketed by 38bps to 1.75% in 2023, then skyrocketed by 65bps to 0.61% in 2024, then grew by 24bps to 0.46% in 2025.
  • Per Business Quant, the three most recent readings for MDGL's Return on Equity are 0.46% (Q4 2025), 0.43% (Q3 2025), and 0.4% (Q2 2025).